DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Alpha-Galactosidase A (Alpha-D-Galactosidase A or Alpha-D-Galactoside Galactohydrolase or Melibiase or EC 220.127.116.11) - Pipeline Review, H1 2016" report to their offering.
This report provides comprehensive information on the therapeutic development for Alpha-Galactosidase A, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alpha-Galactosidase A and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Alpha-Galactosidase A Overview
- Therapeutics Development
- Pipeline Products for Alpha-Galactosidase A - Overview
- Pipeline Products for Alpha-Galactosidase A - Comparative Analysis
- Alpha-Galactosidase A - Therapeutics under Development by Companies
- Alpha-Galactosidase A - Therapeutics under Investigation by Universities/Institutes
- Alpha-Galactosidase A Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Alpha-Galactosidase A - Products under Development by Companies
- Alpha-Galactosidase A - Products under Investigation by Universities/Institutes
- Alpha-Galactosidase A - Companies Involved in Therapeutics Development
- Amicus Therapeutics, Inc.
- greenovation Biotech GmbH
- iBio, Inc.
- ISU ABXIS Co.,Ltd.
- JCR Pharmaceuticals Co., Ltd.
- Pharming Group N.V.
- Protalix BioTherapeutics, Inc.
- Shire Plc
For more information visit http://www.researchandmarkets.com/research/cngvzv/alphagalactosidas